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Research
Parkinson’s disease (PD), an age-related neuro-
degenerative disorder, progresses over decades. 
The mechanism for the gradual loss of nigral 
dopamine (DA) neurons and the chronic dis-
ease progression in PD is largely unknown. 
Emerging evidence has indicated that neuro-
inflammation contributes to PD (Block et al. 
2007; Gao and Hong 2008; Hirsch and 
Hunot 2009). Morphologic changes of micro-
glia (the resident brain immune cells) and 
accumulation of pro  inflammatory factors are 
associated with degenerating DA neurons in 
the substantia nigra (SN) of PD patients and 
various PD animal models (Liberatore et al. 
1999; McGeer et al. 1988; Sherer et al. 2003). 
DNA polymorphisms of several inflammatory 
cytokines and genetic variation in the HLA 
(human leukocyte antigen) region that con-
tains numerous immune-related genes might 
increase the risk of PD (Hamza et al. 2010; 
Wahner et al. 2007). Moreover, inhibition of 
inflammation is associated with reduced neu-
ronal impairment in various PD models (Gao 
et al. 2003; Wu et al. 2003). We and others 
previously reported that an intra  peritoneal 
injection or chronic nigral infusion of rela-
tively high doses of lipo  polysaccharide (LPS; a 
common inflammogen) led to time-dependent 
degeneration of nigral DA neurons in rodents 
(Gao et al. 2002; Ling et al. 2006; Qin et al. 
2007). However, mechanisms through which 
an acute neuro  inflammatory response is trans-
formed into a chronic inflammatory process, 
and chronic neuro  inflammation influences 
progressive neuro  degeneration, require further 
investigation.
Numerous  mutations  in  multiple 
genes have been identified in familial PD. 
α-Synuclein (α-syn) is closely associated with 
both familial and sporadic PD. Missense 
mutations (A53T, A30P, and E46K) and 
multiplications of the α-syn gene (SNCA) 
cause autosomal-dominant PD (Farrer 2006; 
Krüger et al. 1998; Polymeropoulos et al. 
1997). Disease severity in PD patients with 
SNCA multiplications positively correlates 
with gene copy number (Chartier-Harlin 
et al. 2004; Ibanez et al. 2004; Singleton et al. 
2003). Common variability in SNCA has been 
associated with a greater risk of sporadic PD 
(Pals et al. 2004). Additionally, age-related 
increases of α-syn in monkeys and humans 
are linked to nigrostriatal DA depletion (Chu 
and Kordower 2007). Furthermore, α-syn 
aggregates are the primary component of 
Lewy bodies in both familial and sporadic PD 
(Spillantini et al. 1997). The occurrence of 
α-syn–positive inclusions in neurons grafted 
into the brains of PD patients and a trans-
genic (Tg) PD model (Desplats et al. 2009; 
Kordower et al. 2008; Li et al. 2008; Mendez 
et al. 2008) further emphasizes a pivotal role 
of α-syn in ongoing disease progression and 
host-to-graft disease propagation.
The current consensus suggests that PD 
develops from complex gene–environment 
interactions. For the present study, we cre-
ated a two-hit, chronic, progressive model 
that we used to investigate mechanisms of 
PD progression. Specifically, we examined 
how mutant human α-syn and low-grade 
neuro  inflammation inter  acted and influenced 
PD neuro  degeneration and disease progres-
sion in Tg mice over  expressing A53T mutant 
human α-syn. We intraperitoneally injected a 
relatively low dose of LPS (3 × 106 EU/kg) to 
induce systemic inflammation that transferred 
into the brain to form a comparatively mild 
neuro  inflammatory response.
Materials and Methods
Animals and the LPS injection. Male homo-
zygous α-syn Tg mice and B6C3F1/J mice 
[wild-type (WT) controls] were obtained from 
the Jackson Laboratory (Bar Harbor, ME) and 
treated humanely and with regard for allevia-
tion of suffering following the NIH Guide for 
Care and Use of Laboratory Animals (Institute 
of Laboratory Animal Resources 1996). The 
Tg mice were generated on a C57BL/C3H 
background and expressed endogenous α-syn 
and human A53T mutant α-syn driven by a 
mouse prion protein promoter (Giasson et al. 
2002). Seven-month-old WT and Tg mice 
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Ba c k g r o u n d: Mechanisms whereby gene–environment interactions mediate chronic,   progressive 
neuro  degenerative processes in Parkinson’s disease (PD)—the second most common neuro­
degenerative disease—remain elusive.
oB j e c t i v e: We created a two­hit [neuro  inflammation and mutant α­synuclein (α­syn) over­
expression] animal model to investigate mechanisms through which mutant α­syn and inflamma­
tion work in concert to mediate chronic PD neuro  degeneration.
Me t h o d s : We used an intraperitoneal injection of the inflammogen lipopolysaccharide (LPS; 
3 × 106 EU/kg) to initiate systemic and brain inflammation in wild­type (WT) mice and transgenic 
(Tg) mice over  expressing human A53T mutant α­syn. We then evaluated nigral dopaminergic 
neuro  degeneration, α­syn pathology, and neuro  inflammation. 
re s u l t s: After LPS injection, both WT and Tg mice initially displayed indistinguishable acute 
neuro  inflammation; however, only Tg mice developed persistent neuro  inflammation, chronic pro­
gressive degeneration of the nigrostriatal dopamine pathway, accumulation of aggregated, nitrated 
α­syn, and formation of Lewy body­like inclusions in nigral neurons. Further mechanistic studies 
indicated that 4­week infusion of two inhibitors of inducible nitric oxide synthase and NADPH 
oxidase, major free radical–generating enzymes in activated microglia, blocked nigral α­syn pathol­
ogy and neuro  degeneration in LPS­injected Tg mice.
co n c l u s i o n s: Microglia­derived oxidative stress bridged neuro  inflammation and α­syn pathogenic 
alteration in mediating chronic PD progression. Our two­hit animal model involving both a genetic 
lesion and an environmental trigger reproduced key features of PD and demonstrated synergistic 
effects of genetic pre  disposition and environmental exposures in the development of PD. The 
chronic progressive nature of dopaminergic neuro  degeneration, which is absent in most existing PD 
models, makes this new model invaluable for the study of mechanisms of PD progression.
key w o r d s : α­synuclein, gene–environment interaction, inflammation, iNOS, microglia, 
NADPH oxidase, neuro  degeneration, oxidative stress, Parkinson’s disease. Environ Health Perspect 
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received an intra  peritoneal injection of normal 
saline (NS) or LPS (Escherichia coli 0111:B4; 
3 × 106 EU/kg). Four-week infusion of 1400W 
[an inhibitor of inducible nitric oxide syn-
thase (iNOS); 50 μg/kg/hr] and diphenylene-
iodonium (DPI; a NADPH oxidase inhibitor; 
5 μg/kg/hr) or vehicle (phosphate-buffered 
saline containing 6% DMSO) via osmotic 
mini  pumps (0.25 μL/hr; 90 μL total capacity; 
replaced once) was started 30 min before the 
intra  peritoneal injection of NS/LPS. None of 
the Tg mice presented overt neuro  logic impair-
ment at the time of LPS/NS injection. Mice 
were euthanized at desired time points in an 
age-matched fashion.
Immmunohistochemistry,  confocal 
  double-label immuno  fluorescence, and cell 
counting. We used the following primary anti-
bodies for immuno  staining, confocal double-
label immuno  fluorescence, and cell counts: 
SYN211 (1:500; Millipore, Billerica, MA), 
nSYN514 (1:150; Santa Cruz Biotechnology, 
Santa Cruz, CA), and anti  bodies against a 
neuron-specific nuclear protein (Neu-N; 
1:2,000; Chemicon, Billerica, MA), tyrosine 
hydroxylase (TH; 1:1,000; Sigma Chemical 
Company, St. Louis, MO), or ionized cal-
cium binding adaptor molecule-1 (Iba-1; 
1:500; Wako Chemicals, Richmond, VA). For 
details of immuno  staining assays and count-
ing of immuno  stained cells, see Supplemental 
Material (doi:10.1289/ehp.1003013). Briefly, 
we incubated 30-μm brain sections with 99% 
formic acid for 5 min for antigen retrieval 
before performing double-label immmuno-
histo  chemistry using nSYN514 and Neu-N 
anti  bodies. Sections were then incubated 
with Alexa-488 (green) and Alexa-594 (red) 
conjugated secondary antibodies (1:1,000), 
both from Invitrogen (Carlsbad, CA). We 
counterstained the nuclei with DAPI (4´,6-
diamidino-2-phenylindole). To monitor DA 
neuro  degeneration, two individuals blind 
to the treatment counted the number of 
TH-immunoreactive (TH-IR) neurons in the 
SN pars compacta (SNpc) of six evenly spaced 
brain sections from a series of 24 sections that 
covered the entire SN (Zhang et al. 2004).
Sequential biochemical fractiona  tion and 
Western blotting. Sequential protein extraction 
initially removed highly soluble proteins using 
high-salt (HS) buffer. Proteins from insoluble 
pellets were then extracted using buffers with 
increasing solubilization strength: HST buf-
fer (HS buffer containing 1% Triton X-100), 
RIPA (radio  immuno  precipitation assay) buf-
fer, and 2% sodium dodecyl sulfate (SDS). For 
all other biochemical studies, we used the 2% 
SDS buffer to extract both soluble and aggre-
gated proteins from stratum, SN, or whole 
brains (Gao et al. 2008; Giasson et al. 2002). 
For Western blotting, we used the follow-
ing primary antibodies: SYN211 (1:1,000), 
nSYN514 (1:250), α-synuclein (C-20)-R 
(reactive to mouse, rat, and human α-syn; 
Santa Cruz Biotechnology), or anti  bodies spe-
cific for iNOS (1:500), macro  phage antigen 
complex 1 (Mac1; 1:1,000), TH (1:5,000), 
Neu-N (1:500), cyclo  oxygenase-2 (COX-2; 
Figure 1. α-Syn Tg mice were more sensitive to inflammation-mediated neurotoxicity. (A) Time-dependent loss of nigral DA neurons in α-syn Tg mice, but not WT 
mice, after LPS injection. (B) Densitometry analysis revealed a 46% decrease in striatal TH immunostaining in Tg mice 5 months after LPS injection. In A and B, 
numbers within the bars indicate the number of mice in each group at each time point. (C and D) Representative brain images with TH immunostaining 5 months 
after LPS injection indicate prominent dopaminergic lesions of SN (C) and striatum (D) in Tg mice but not in WT mice. (E) In the SN of LPS-injected Tg mice, the 
loss of DA neurons (double-labeled with anti-TH antibody in cytoplasm and anti–Neu-N antibody in nuclei) 5 months after LPS was greater than that of non-DA 
neurons (green nuclear Neu-N staining only). The inset shows a double-labeled DA neuron. In inset, bar = 10 µm. 
*p < 0.05 compared with the corresponding NS-injected control. 
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1:1,000), or gp91phox (1:2,000). We included 
monoclonal anti-β-actin antibody (1:5,000) 
as an internal standard to monitor loading 
errors (Gao et al. 2008; Giasson et al. 2002). 
See Supplemental Material (doi:10.1289/
ehp.1003013) for details.
Statistical analysis. All values are expressed 
as mean ± SE. Differences among means were 
analyzed using one- or two-way analysis of 
variance (ANOVA) with treatment or geno-
type as independent factors. When ANOVA 
showed significant differences, pairwise 
compari  sons between means were tested by 
Newman-Keuls post hoc testing. In all analy-
ses, the null hypothesis was rejected at the 
0.05 level.
Results
Delayed progressive nigral neuro  degeneration 
in α-Syn Tg mice, but not WT mice, after LPS 
challenge. Both α-syn and neuro  inflammation 
are implicated in PD, but it is unclear how 
their inter  action affects chronic progression of 
PD. Additionally, for unknown reasons, most 
available α-syn Tg mice fail to develop overt 
nigral DA neuro  degeneration while exhibiting 
widespread α-syn pathology in the central ner-
vous system (Giasson et al. 2002). We there-
fore created a chronic, two-hit mouse model 
to investigate whether inflammation enhances 
α-syn pathogenic alteration and accelerates 
neuro  degeneration and disease progression. 
After LPS injection, Tg mice, but not WT 
mice, developed delayed, chronic and pro-
gressive degeneration of nigral DA neurons, 
as shown by time-dependent decreases in the 
number of TH-IR neurons (Figure 1A–D). 
In particular, 5 months after LPS injection, 
Tg mice lost 58% of nigral DA neurons 
(Figure 1A), whereas their striatal TH levels 
were reduced by 46% (Figure 1B). In contrast, 
neither nigral DA neurons nor striatal TH 
levels were altered significantly in LPS-injected 
WT mice compared with NS-injected WT 
mice. We identified synergistic neuro  toxicity 
of LPS treatment and α-syn over  expression 
when the difference in cell loss between 
NS-injected WT mice and LPS-injected Tg 
mice was significantly greater than the sum of 
cell loss observed in NS-injected Tg mice (i.e., 
mice with the geno  type but not the environ-
mental exposure) and LPS-injected WT mice 
(i.e., mice with the environmental exposure 
only). TH immunostaining demonstrated the 
destruction of nigral DA neurons and striatal 
DA fibers in LPS-injected Tg mice, whereas 
the nigro  striatal pathway in NS-injected 
Tg mice and all WT mice remained intact 
(Figure 1C,D). The relative selectivity of nigral 
neuro  degeneration was characterized by dou-
ble-label immuno  fluorescence (Figure 1E). 
In the SNpc of LPS-injected Tg mice, the 
number of DA neurons (TH+/Neu-N+) was 
decreased by 52 ± 5.6%, whereas non-DA 
neurons (TH–/Neu-N+) were relatively spared, 
as indicated by a 9.2 ± 4.9% reduction. Here, 
the average number of DA neurons (TH+/
Neu-N+) and non-DA neurons (TH–/Neu-N+) 
per SNpc region in the NS-injected Tg was 
96 ± 7.4 and 51 ± 9.1, respectively. Moreover, 
Western blotting (Figure 5) showed that in 
LPS- versus NS-injected Tg mice, there was 
a 53% reduction in nigral TH (indicating 
loss of DA neurons) and a 20% reduction 
in nigral Neu-N (indicating loss of DA neu-
rons and probably some non-DA neurons in 
the SN) 5 months after LPS administration. 
Consistent with the pattern of neuronal loss 
observed in PD patients, the destruction of 
nigral DA neurons was not accompanied by 
significant damage to DA neurons in the adja-
cent ventral tegmental area. The numbers of 
TH-IR neurons in the ventral tegmental area 
of Tg mice 5 months after the injection were 
159 ± 8.19 (NS; n = 4) and 154 ± 5.18 (LPS; 
n = 4). Collectively, this two-hit PD model 
reproduced the signature lesion of PD, the 
relatively selective degeneration of DA   neurons 
in the SN.
Accumulation and pathologic modification 
of insoluble, aggregated α-syn in LPS-injected 
Tg mice. In addition to developing progres-
sive neuro  degeneration, LPS-injected Tg mice 
accumulated more α-syn in the whole brain 
5 months after injection than did NS-injected 
Tg mice (Figure 2A). Next, sequential extrac-
tion using buffers with increasing solubiliza-
tion strength detected highly insoluble α-syn in 
midbrain SDS fractions of Tg mice 5 months 
after LPS injection. By contrast, midbrain α-syn 
of NS-injected Tg mice and age-matched WT 
mice injected with NS/LPS was soluble in HS 
and HST buffers (Figure 2B). Unlike midbrains, 
the cortex and spinal cord of 12-month-old 
Tg mice displayed age-related accumulation of 
insoluble α-syn in the absence of any treatment 
(data not shown), which was in accordance with 
earlier observations (Giasson et al. 2002).
Figure 2. Accumulation of insoluble and aggregated α-syn after LPS injection. (A) Five months after treat-
ment, LPS-injected Tg mice accumulated more α-syn in the whole brain than did NS-injected Tg mice, as 
shown by immuno    blotting using SYN211 antibody (specific for human α-syn) and summarized in the graph. 
(B) Sequential extraction detected RIPA-insoluble α-syn in midbrains of LPS-injected Tg mice; α-syn of 
WT mice was recovered only in HS- and HST-soluble fractions. In A and B, each lane is the most repre-
sentative sample from among at least three different animals. (C). In contrast with diffuse and faint α-syn 
staining observed in the SN of NS-injected Tg mice 5 months after the injection (left), α-syn (red) in LPS-
injected Tg mice (center) appeared mainly in peri  nuclear locations and formed aggregates; magnifications 
(right) are from areas indicated in the LPS section (center). 
*p < 0.05 compared with the NS-injected control.
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Immunofluorescence analysis revealed 
accumulation of α-syn–positive aggregates in 
peri  nuclear locations in the SN of LPS-injected 
Tg mice (Figure 2C). nSYN514 antibody 
(specific for nitrated human α-syn) positively 
stained these aggregates (Figure 3A). Double-
label immuno  fluorescence demonstrated α-syn 
aggregates in TH-IR neurons in the SN of 
LPS-injected Tg mice (Figure 3B). Moreover, 
nitrated α-syn accumulated in neurons to 
form cytoplasmic inclusions (Figure 3C). In 
contrast, nigral α-syn immunoreactivity in 
NS-injected Tg mice was diffuse and barely 
visible (Figures 2C and 3A–C). In midbrains 
of LPS-injected but not NS-injected Tg mice, 
immunoblotting also detected nitrated human 
α-syn, which appeared predominantly in HS- 
and HST-insoluble fractions (Figure 3D,E). 
Thus, in this two-hit model, LPS-induced 
inflammation accelerated α-syn accumulation, 
aggregation, and nitration.
Similar acute systemic and brain inflam-
matory reactions in WT and Tg mice after LPS 
injection. To determine the basis for differential 
nigral α-syn pathology and neuro  degeneration 
in Tg and WT mice after LPS exposure, we first 
examined acute inflammation in these mice. Tg 
and WT mice reacted to LPS in an indistin-
guishable way. Serum tumor necrosis factor-α 
(TNF-α) and interleukin-1β (IL-1β) were 
greatly increased to similar levels after LPS injec-
tion in both genotypes, implying that geno  type 
did not alter acute systemic inflammation in 
response to LPS [see Supplemental Material, 
Figure 1A (doi:10.1289/ehp.1003013)]. We 
chose TNF-α and IL-1β as representative 
indicators of systemic inflammation because 
both cyto  kines are crucial for systemic effects of 
inflammation, including fever, increased heart 
rate, and sepsis, and because TNF-α was one of 
the major pro  inflammatory cyto  kines respon-
sible for transferring peripheral inflammation 
to the brain when LPS was intra  peritoneally 
injected into mice (Qin et al. 2007).
The absence of detectable differences 
between WT and Tg mice in the expression 
of Mac1 and Iba-1 in the brain 1 day after 
LPS injection suggests similar acute neuro-
inflammatory responses in both geno  types. 
Microglia in the SN displayed similar acute 
morphologic transformation from rest-
ing to activated states in both types of mice 
[see Supplemental Material, Figure 1B–D 
(doi:10.1289/ehp.1003013)]. Thus, the acute 
systemic and brain inflammatory reactions to 
LPS were not distinguishably different in Tg 
and WT mice.
Association of α-Syn pathology and progres-
sive nigral neuro  degeneration with prolonged 
neuro  inflammation. We next detected chronic 
nigral neuro  inflammation in Tg mice, but not 
WT mice (Figure 4). Five months after LPS 
injection, nigral microglia of Tg mice were acti-
vated, exhibiting enlarged cell bodies, elevated 
Figure 3. Nitration of aggregated α-syn and formation of cytoplasmic inclusions in Tg mice 5 months after 
LPS injection. (A) Nitrated human α-syn (labeled with nSYN514 antibody) formed aggregates and was 
mainly peri  nuclear in the SN of LPS-injected Tg mice (center), whereas nSYN514 staining in NS-injected 
Tg mice (left) was scant. Magnifications (right) are from areas shown in the LPS section. (B) The SN of 
LPS-injected Tg mice contained human α-syn aggregates (red) in TH-IR neurons (green). (C) Cytoplasmic 
inclusions containing nitrated human α-syn (brown) in nigral neurons (with nuclei stained in dark blue) 
indicated by red arrows in LPS-injected Tg mice (center) and magnified photo  micrographs (right) from 
the LPS section. The SN of NS-injected Tg mice (left) did not exhibit obvious staining for nitrated α-syn. 
(D) Western blotting shows nitrated human α-syn in midbrain extracts from LPS-injected Tg mice but not 
NS-injected Tg mice. (E) The accumulation of nitrated human α-syn was observed primarily in RIPA and 
SDS fractions from midbrains of Tg mice. At least four mice in each group were used for immuno  staining 
and immuno  blotting. For magnifications in C, bars = 10 µm. 
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expression of Iba-1, and increased density in 
the SN. Microglia of LPS-injected WT mice 
revealed ramified resting morphology; levels 
of Iba-1 expression in microglia were similar 
in LPS-injected and NS-injected WT mice 
(Figure 4). Five months after LPS exposure, 
we observed marked up-regulation of multiple 
inflammatory markers, including Iba-1, Mac1, 
iNOS, COX-2, and gp91phox, in both the SN 
and striatum of Tg mice, indicating prolonged 
neuro  inflammation in these regions (Figure 5).
By repeatedly probing, stripping, and 
reprobing the same immuno  blotting mem-
branes, we observed that the persistent neuro-
inflammation was negatively correlated with 
TH levels and positively correlated with α-syn 
levels in both the SN and striatum of LPS-
injected Tg mice (Figure 5). In concurrence 
with elevated inflammatory mediators, α-syn 
levels in the SN and striatum showed 80% and 
60% increases, respectively, and TH levels were 
decreased by approximately 50% (Figure 5). 
The more pronounced increase in α-syn expres-
sion in the SN and striatum (60–80%) than 
in the whole brain (28%; Figure 2A) of LPS-
challenged Tg mice may be attributable, at 
least partially, to the high density of microglia 
(Kim et al. 2000) and more marked inflamma-
tory responses in these brain regions.
Unlike LPS-injected Tg mice, NS-injected 
Tg mice and LPS-injected WT mice failed to 
develop chronic neuro  inflammation (Figure 4), 
α-syn pathology (Figures 2 and 3), or detect-
able neuronal loss (Figures 1, 4, and 5) in the 
nigro  striatal pathway. These data together 
demonstrate that chronic progression of PD 
was driven by synergistic effects of low-grade 
neuro  inflammation and α-syn dysfunction. 
In contrast, neither factor appeared to be suf-
ficient to cause neuronal death in isolation.
Continuous inhibition of iNOS and 
NADPH oxidase blocked α-syn pathology and 
nigral neuro  degeneration. NADPH oxidase 
and iNOS are major free radical–  generating 
enzymes in activated microglia. The marked 
up-regulation of iNOS and gp91phox (the 
catalytic subunit of NADPH oxidase) in the 
nigro  striatal pathway of LPS-injected Tg 
mice (Figure 5A,B) prompted us to hypothe-
size that microglia-derived free radicals (e.g., 
superoxide, nitric oxide, and their reaction 
product peroxy  nitrite) caused the nitration of 
α-syn, which in turn promoted formation of 
α-syn aggregates and sensitized DA neurons to 
diverse insults. Inhibition of NADPH oxidase 
and iNOS by 4-week infusion of DPI and 
1400W reduced chronic neuro  inflammation 
Figure 4. Association between progressive nigral neurodegeneration and prolonged neuroinflammation. Double-label immunofluorescence shows loss of 
TH-positive DA neurons and degeneration of DA fibers in the SN of α-syn Tg mice 5 months after LPS injection. Only in LPS-injected Tg mice did microglia show 
active morphology: elevated expression of Iba-1 (red), larger size, irregular shape, and increased numbers in the SN. Microglia of WT mice exhibit resting rami-
fied morphology. Magnifications (right) are from areas indicated in the merged column. All images are representative samples from among at least three different 
animals in each group. 
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(Figure 6A,B,E), blocked nigral α-syn pathol-
ogy (Figure 6A–C,E), and prevented dopamin-
ergic neuro  degeneration (Figure 5A,B,D,E) in 
Tg mice 3 months after LPS exposure. Within 
the brain, both iNOS and NADPH oxidase 
are primarily located in microglia. Therefore, 
the attenuation of Mac1, gp91phox, and iNOS 
up-regulation by 1400W and DPI implies 
that microglia-derived free radicals played a 
critical role in maintaining chronic neuro-
inflammation (Figure 6A,B). The correlation 
of dampened neuro  inflammation with abol-
ished nitration of α-syn, reduced accumulation 
of insoluble α-syn, and attenuated neuronal 
impairment is consistent with a causative 
relationship between inflammation-mediated 
α-syn pathologic alterations and chronic dop-
aminergic neuro  degeneration.
Discussion
The present study demonstrates that persistent 
neuro  inflammation bridges α-syn pathologic 
alterations and progressive neuro  degeneration in 
mediating chronic PD progression. The two-hit 
(neuro  inflammation and mutant α-syn over-
expression) progressive animal model created 
for this study mimics PD multifactorial etiol-
ogy and reproduces the following key features 
of PD: a) chronic, progressive, and relatively 
selective degeneration of dopaminergic neurons 
and fibers in the nigro  striatal pathway; b) Lewy 
body-like neuronal inclusions containing aggre-
gated α-syn; c) persistent neuro  inflammation, 
a common feature shared by all neuro-
degenerative diseases including PD; and d) a 
chronic progressive disease course that is absent 
in most available PD models. These key features 
of PD were replicated in LPS-injected α-syn 
Tg mice, but not in NS-injected Tg mice or in 
LPS-injected WT mice, indicating synergistic 
effects of environmental exposures and genetic 
predisposition in the pathogenesis of PD.
α-Syn plays a prominent role in PD 
onset, on  going disease progression, and host-
to-graft disease propagation. In general, Tg 
over  expression of human α-syn results in 
widespread α-syn pathologies and variable 
neuro  degeneration in different animal spe-
cies (Farrer 2006; Lee et al. 2002). Among 
different α-syn Tg mouse models, only a few 
exhibit overt degeneration of nigro  striatal DA 
fibers and even fewer show loss of nigral DA 
neurons (Dawson et al. 2010; Lee et al. 2002; 
Masliah et al. 2000). The lack of DA neuron 
loss in most gene-based PD animal models 
and the dearth of α-syn pathology in most 
toxin-based PD animal models under  score a 
crucial role of gene–environment inter  actions 
in PD. The low rate of concordance for PD 
in mono  zygotic and dizygotic twins (Marttila 
et al. 1988; Tanner 2003) strongly suggests 
the involvement of environmental factors in 
PD. Epidemiologic and case–control studies 
have implicated rural living, well water con-
sumption, and pesticide exposure as potential 
environ  mental risk factors for PD (Elbaz et al. 
2009). Interestingly, it has been reported that 
over  expression of mutant α-syn in mice pro-
tects against (Manning-Bog et al. 2003) or fails 
to affect paraquat neuro  toxicity (Norris et al. 
2007), augments neuro  degeneration elicited 
by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine and LPS (Gao et al. 2008; Nieto et al. 
2005), or does not enhance rotenone-induced 
neuro  toxicity (Nieto et al. 2005). These find-
ings indicate that inter  actions between α-syn 
and environ  mental toxins on PD neuro-
degeneration require further investigation. 
Another newly developed two-hit mouse 
model combining a genetic lesion (Parkin–/–) 
and neuro  inflammation has provided addi-
tional experimental evidence supporting a cru-
cial role of gene–environment interactions in 
PD (Frank-Cannon et al. 2008).
Compared with a previous mouse model, 
generated by an intra  peritoneal injection 
of a higher dose of LPS (5 mg/kg, equal to 
~ 15 × 106 EU/kg) into WT mice (Qin et al. 
2007), our two-hit model created by a mod-
erately toxic dose of LPS (3 × 106 EU/kg) 
revealed accelerated DA neuro  degeneration 
and provided additional insight into α-syn 
pathologic alterations under inflammatory 
states. Specifically, significant loss of DA neu-
rons started to manifest at 7 months after LPS 
injection in the prior model (Qin et al. 2007) 
and at 2.5 months in our two-hit model; at 
these two time points, a 23% and 37% loss 
of DA neurons was observed, respectively. A 
Figure 5. Association of neurodegeneration with chronic α-syn accumulation and prolonged neuroinflammation. Five months after LPS injection, Tg mice dis-
played significant decreases in TH levels, marked up-regulation of multiple inflammatory markers (Mac1, Iba-1, gp91, iNOS, and COX-2), and accumulation of 
α-syn in the SN (A and B) and striatum (C and D). NS-injected 12-month-old Tg mice did not show overt changes in levels of TH, α-syn, or inflammatory markers, 
in contrast with 2-month-old Tg mice. Graphs (B and D) show the ratio of densitometry values (mean ± SE) of each examined protein, and β-actin was normalized 
to each respective NS-injected control. All immunoblot lanes are representative samples from among at least three different animals in each group. 
*p < 0.05 compared with corresponding NS-injected control mice. 
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single nigral injection of LPS resulted in acute, 
dramatic nigral neuro  inflammation and DA 
neuron loss in mutant α-syn Tg mice (Gao 
et al. 2008), but that acute two-hit model did 
not replicate the chronic, progressive course 
of PD, and acute, robust, and localized nigral 
inflammation may not be highly relevant to 
potential etiologies or pathogenesis of PD. The 
present study therefore advances research to 
elucidate a mechanistic link among persistent 
neuro  inflammation, chronic α-syn pathology, 
and progressive neuro  degeneration in chronic 
PD progression.
Persistent activation of iNOS and NADPH 
oxidase in LPS-treated Tg mice (Figure 5) and 
blockage of nitrated α-syn formation by con-
tinuous inhibition of these enzymes (Figure 6) 
indicated that increased nitric oxide, super-
oxide, and peroxy  nitrite may nitrosylate and/or 
oxidize α-syn and lower its solubility to form 
aggregates (Figures 2 and 3). Aggregated α-syn 
may over  whelm the ubiquitin–proteasome 
system and accumulate over time, leading to 
endoplasmic reticulum stress and mitochon-
drial impairment (Cooper et al. 2006). Loss 
of physiologic function of normal α-syn and 
oxidative insults from microglia-derived free 
radicals further exacerbate neuronal damage, 
eventually causing neuronal death. DA neurons 
in the SN are known to be uniquely vulnerable 
to oxidative insults (Jenner and Olanow 1998), 
and they encounter an excessively high level 
of oxidative stress during brain inflammation 
because of the high density of microglia in this 
region (Kim et al. 2000). The combination of 
these factors may be partially responsible for 
the relatively selective degenera  tion of DA neu-
rons in the SN in PD.
We have proposed that dying/dead neu-
rons further activate microglia by releasing 
noxious compounds (e.g., α-syn) into the 
extra  cellular milieu (Gao and Hong 2008). 
Indeed, monomeric and aggregated α-syn can 
be released from cultured cells and is recovered 
from the cerebro  spinal fluid of patients with 
PD (Liu et al. 2009). Exogenous application of 
aggregated α-syn activates cultured microglia 
(Zhang et al. 2005). Therefore, ongoing neuro-
degeneration and chronic neuro  inflammation 
cause a vicious self-propelling cycle that makes 
it possible for neuro  inflammation to per-
sist long after peripheral inflammation has 
abated, and for neuro  degeneration to become 
a chronic progressive process. Without posi-
tive feedback from damaged neurons, the low-
grade acute neuro  inflammation induced by 
LPS was not sustained in WT mice, and con-
sequent effects on α-syn pathology and neuro-
degeneration were negligible.
Conclusions
Our two-hit progressive model underscores a 
central role of gene–environment inter  actions 
in the development of PD. The attenuation 
of nigral α-syn pathology and dopaminergic 
neuro  degeneration by the inhibition of inflam-
matory enzymes—  NADPH oxidase and 
iNOS—strongly supports a causa  tive relation-
ship between inflammation-  mediated α-syn 
pathologic alterations and chronic dopamin-
ergic neuro  degeneration. Microglia-derived 
free radicals were major factors that bridged 
neuro  inflammation and α-syn dysfunction in 
mediating chronic PD neuro    degeneration.
Figure 6. Inhibition of iNOS and NADPH oxidase prevent chronic dopaminergic neuro  degeneration and α-syn 
pathology in LPS-injected Tg mice. (A) Immunoblotting analysis of midbrain proteins extracted by 2% SDS 
buffer indicates that a 4-week infusion of 1400W and DPI blunted up-regulation of inflammatory markers 
(Mac1, iNOS, and gp91phox), attenuated loss of TH, and reduced accumulation of nitrated α-syn in Tg mice 
3 months after LPS injection. (B) Densitometry analysis of proteins and β-actin examined in A; Results are 
mean ± SE normalized to the corresponding NS-injected control. (C) Accumulation of nitrated human α-syn 
with low solubility in RIPA and SDS fractions from midbrains of Tg mice 3 months after LPS injection, which 
was blocked by 1400W and DPI. (D) Blockage of chronic degeneration of nigral DA neurons in α-syn Tg mice 
3 months after LPS injection by 1400W and DPI. (E) Representative brain images of α-syn Tg mice 3 months 
after LPS indicate that a 4-week infusion of 1400W and DPI dampened chronic microglial activation, attenu-
ated accumulation of α-syn, and reduced nigral DA lesions. Insets are magnified photomicrographs of cor-
responding images. In insets, bar = 25 μm. For immuno  blotting and immuno  staining, n = 4 mice per group. 
*p < 0.05 compared with corresponding NS-injected control mice; #p < 0.05 compared with corresponding LPS-injected mice. 
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